Kaya Ltd

- Kaya Limited is planning a rights issue with a quantum of up to INR 300 crores. - The promoters are committed to subscribing mainly to this rights issue. - The rights issue process will start after the completion of the Kaya DMCC sale, subject to authorities' approval. - Current net debt post the Kaya Middle East transaction is INR 143.72 crores, which is fully from directors. - The company has reduced net debt by about INR 50 crores after the transaction completion. - No specific mention of new debt fundraising in the call, focus appears to be on the rights issue for equity capital infusion.

- Kaya Limited plans to open 6 to 8 new clinics in FY'25. - Capex for a new clinic is around INR 1.8 to 2 crore. - Capex for relocating a clinic is lower (exact number not specified on Page 11). - The brand refresh program includes relocations, renovations, and service technology updates. - In Q1 FY'25, three clinics were renovated; 14 renovations have been done since FY'24 started. - Kaya invested in 38 new dermatology machines in Q1 FY'25 focusing on anti-aging, acne, body, and laser hair reduction. - Upcoming product development and innovation continue in-house with a focus on dermatology-based products. - The body contouring segment is growing rapidly, with new machines being added at a faster scale this financial year. (Information primarily from Pages 3, 5, 7, and 11)

- Kaya India clinic business saw 8% revenue growth in Q1 FY'25, driven by categories like body contouring (+25%) and hair care (+14%). - New clinics planned: 6-8 openings in FY'25, expected to contribute 7-8% growth. - Like-for-like clinic growth anticipated at 5-8%. Combined with new clinics, overall growth could be 8-10%. - Marketing spend maintained at 7-8% of net revenue to support growth. - Body contouring and lower-priced services expected to scale faster, potentially driving incremental revenues and profits. - Marico collaboration aims to boost product sales outside clinics (e-commerce, GT/MT), indirectly increasing clinic footfall and revenues. - Average transaction size (ATS) high (INR17,000-22,000), and efforts to enter lower-priced service segments noted. - No concrete long-term revenue or volume forecasts given publicly, but strategy focuses on combined growth via clinic expansion, service innovation, and product sales enhancement.

- Kaya India clinic business showed 8% revenue growth in Q1 FY'25, with body contouring up 25% and hair care up 14%. - The company targets double-digit growth through clinic expansion, relocations, and renovations. - Like-for-like clinic collections grew ~7%, and new clinics are expected to add 7-8% growth annually. - Marketing spends remain ~7-8% of net revenue, supporting growth and brand visibility. - EBITDA profitability target not explicitly given, but strategies aim for economies of scale and higher profitability over time. - Promoters committed to rights issue funding (up to INR 300 crore) to support growth. - With new product development retained in-house and expanded product sales via Marico, overall revenue and footfalls are expected to increase. - No specific EPS or net profit guidance was provided; however, improved operational metrics and strategic initiatives indicate positive future earnings trends.

The transcript and pages provided from the Kaya Limited Q1 FY'25 Earnings Call do not explicitly mention the current or expected order book or pending orders. However, relevant insights related to business growth and initiatives are noted: - Kaya is expanding its clinic network with plans to open 6 to 8 new clinics in the financial year. - Renovations and relocations of clinics continue, with 3 clinics relocated in Q1 FY'25 and a total of 14 renovations since FY'24 start. - Collaboration with Marico for product distribution outside clinics aims to enhance product sales and brand visibility. - Body contouring and hair care segments show strong growth, supporting service revenue expansion. - No specific figures or details on order book or pending orders are disclosed in the call. If detailed order book data is needed, it may be available in other financial disclosures or investor presentations.